Abstract

Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID

Author(s): Riepl Mike, Kaiser Joe

Issue: Jul/Aug 2023 - Volume 27, Number 4

Page(s): 284-293

Download in electronic PDF format for $75
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID Page 1
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID Page 2
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID Page 3
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID Page 4
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID Page 5
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID Page 6
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID Page 7
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID Page 8
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID Page 9
  • Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID Page 10

Abstract

People infected by severe acute respiratory coronavirus 2 (SARS-CoV-2) risk the development of not only acute coronavirus- disease–2019 (COVID-19) — the signs and symptoms of which range from none to severe illness that requires intensive treatment — but also long COVID (i.e., chronic COVID), a cyclical, progressive, multiphasic illness characterized by myriad debilitating conditions that persist long term. In some patients, those sequelae result in psychiatric disorders that can lead to suicide or other forms of self-harm, incidences of which have increased exponentially since before the COVID pandemic. It has been suggested that long COVID develops in an estimated 10% to 35% of people diagnosed as having COVID-19. Because the success of therapy for either form of COVID can be complicated by each patient’s pharmacogenomic profile, personal treatment preferences, medical needs, and/or dosing requirements, we have found that in some people so afflicted, manufactured medications are ineffective or intolerable, and that for those individuals, a customized compound often provides relief and promotes recovery. The primary focus of this article is long COVID. The pathogenesis of that disease is reviewed, therapies for the signs and symptoms it engenders are examined, and 2 compounded formulations effective in treating both acute and chronic COVID-19 are presented.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Jul/Aug 2023
Pg. 284-293
Author(s): Riepl Mike, Kaiser Joe
Jan/Feb 2023
Pg. 12-21
Author(s): Riepl Mike
May/Jun 2023
Pg. 192-200
Author(s): Riepl Mike, Kaiser Joe
Sep/Oct 2023
Pg. 368-380
Author(s): Riepl Mike, Kaiser Joe
Mar/Apr 2023
Pg. 98-107
Author(s): Riepl Mike
Jul/Aug 2020
Pg. 287-295
Author(s): McElhiney Linda F
Jul/Aug 2020
Pg. 268
Author(s): Allen Loyd V Jr
Sep/Oct 2020
Pg. 358-364
Mar/Apr 2021
Pg. 109-113
Jul/Aug 2003
Pg. 288-291
Author(s): Glasnapp Andrew
Jul/Aug 2020
Pg. 316
Author(s): Allen Loyd V Jr
Jul/Aug 2020
Pg. 310
Author(s): Stockton Shelly J
May/Jun 2003
Pg. 188-191
Author(s): Davidson Gigi S
Jul/Aug 2003
Pg. 266-270
Author(s): Kuntz Rachael
Sep/Oct 2002
Pg. 338-343
Author(s): Lascelles B Duncan
Jul/Aug 2021
Pg. 296-297
Author(s): Brunner Scott
Sep/Oct 2022
Pg. 432-435
Jul/Aug 2021
Pg. 268
Author(s): Allen Loyd V Jr
May/Jun 2020
Pg. 194-197
Sep/Oct 2021
Pg. 386-387
Author(s): Brunner Scott